Income Tax department searches premises of Dolo-650 makers

Officials said the department is looking at financial documents, balance sheets and business distributor networks of Micro Labs Ltd

July 06, 2022 08:04 pm | Updated 08:47 pm IST - Bengaluru:

A pack of Dolo-650 tablets. Photo: Special Arrangement

A pack of Dolo-650 tablets. Photo: Special Arrangement

The Income Tax department Wednesday conducted searches at the premises of Bengaluru-based pharmaceutical company Micro Labs Ltd, the manufacturers of Dolo-650 tablet that was widely used by COVID-19 patients during the last over two years, on charges of alleged tax evasion.

Officials said the department is looking at financial documents, balance sheets and business distributor networks of the company as part of the searches.

The PTI has sent queries on the action to the company and a response is awaited.

Some other linked locations of the company in other cities and those of its promoters and distributors are also being covered, they said.

The company said on its website that it was engaged in the making and marketing pharmaceutical products and APIs (Active Pharmaceutical Ingredients) and has 17 manufacturing units across the country apart from conducting business overseas.

Its major pharma products are Dolo-650, Amlong, Lubrex, Diapride, Vildapride, Olmat, Avas, Tripride, Bactoclav, Tenepride-M and Arbitel.

Dolo-650, an analgesic (pain killer) and antipyretic (fever-reducing) was being prescribed by doctors and medical shop owners for coronavirus patients to reduce pain and fever, common symptoms caused by Covid.

In the words of the company, Dolo-650, is "virtually a household name across the country".

The company website showcased a news article, published in February, on its website that said: "The company has sold 350 crore tablets (of Dolo-650) since the Covid-19 outbreak in 2020, and earned revenues of Rs 400 crore in a year." 

The CMD of the company, Dilip Surana, has been quoted in the story.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.